Compare Inovio Pharmaceuticals Inc (INO) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Wheaton Precious Metals Corp trades at $138.65 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 545.2× Inovio Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Wheaton Precious Metals Corp for 66 Days on average.
| INO | WPM | |
|---|---|---|
Market Cap | $112.19M | $61.17B |
Volume | 3,201,278 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $2.65 | $165.72 |
52-Week Low | $0.66 | $94.37 |
Typical Hold Time | 43 Days | 66 Days |
Enterprise Value | $83.51M | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
WPM trades at $138.65, up 3.71% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported record 2025 revenue of $2.31B and net income of $1.47B, with earnings beating estimates in recent quarters. Analyst consensus is strongly bullish with an 80% buy rating and a $164.80 price target. Recent news highlights production growth targets of 1.2M ounces by 2030 and a fully funded pipeline.
The outlook for WPM is positive given robust earnings growth, high profitability margins, and strategic expansion plans. Key risks include execution of growth targets, commodity price volatility, and interest rate sensitivity. The stock offers upside to consensus targets but faces technical resistance near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
